TriangleIsatuximab (NCT05776979)
Isatuximab trial for Multiple Myeloma (NCT05776979). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–72 with newly diagnosed, high-risk multiple myeloma after an autologous stem-cell transplant. At least a partial response and adequate blood-count recovery are required; progressing disease is excluded.
The idea: add infused isatuximab, which targets CD38 on myeloma cells, to oral lenalidomide, which affects immune activity and cell growth. Maintenance begins about 60–180 days after transplant and may continue for three years.
This phase 2 study plans 61 patients. Muzzaffar Qazilbash leads at MD Anderson in Houston, the sole recruiting US site. Researchers assess disease control and safety.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.